产品
编 号：F010585
分子式：C17H23N5O
分子量：313.4
分子式：C17H23N5O
分子量：313.4
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1020412-43-4
产品详情
生物活性：
Gardiquimod, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 when used at concentrations below 10?μM.
体内研究：
Dendritic cells (DCs) in combination with Gardiquimod (1 mg/kg per mouse; i.p.; daily for 7 days) improves the anti-tumor effects of NK cells.Animal Model:Male athymic nude mice (Balb-nu/nu, 5 weeks old) (bearing human HepG2 liver carcinoma xenografts)
Dosage:1 mg/kg per mouse
Administration:i.p.; daily for 7 days
Result:Significantly suppressed the growth of human HepG2 liver carcinoma xenografts.
体外研究：
Gardiquimod (6-60?μM ) significantly inhibits cDNA synthesis by HIV-1 reverse transcriptase.
Gardiquimod, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 when used at concentrations below 10?μM.
体内研究：
Dendritic cells (DCs) in combination with Gardiquimod (1 mg/kg per mouse; i.p.; daily for 7 days) improves the anti-tumor effects of NK cells.Animal Model:Male athymic nude mice (Balb-nu/nu, 5 weeks old) (bearing human HepG2 liver carcinoma xenografts)
Dosage:1 mg/kg per mouse
Administration:i.p.; daily for 7 days
Result:Significantly suppressed the growth of human HepG2 liver carcinoma xenografts.
体外研究：
Gardiquimod (6-60?μM ) significantly inhibits cDNA synthesis by HIV-1 reverse transcriptase.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备